WO2023187384A1 - Collecte et test microfluidiques - Google Patents

Collecte et test microfluidiques Download PDF

Info

Publication number
WO2023187384A1
WO2023187384A1 PCT/GB2023/050832 GB2023050832W WO2023187384A1 WO 2023187384 A1 WO2023187384 A1 WO 2023187384A1 GB 2023050832 W GB2023050832 W GB 2023050832W WO 2023187384 A1 WO2023187384 A1 WO 2023187384A1
Authority
WO
WIPO (PCT)
Prior art keywords
test
layer
chamber
inlet
test strip
Prior art date
Application number
PCT/GB2023/050832
Other languages
English (en)
Inventor
Richard White
Cedric Hurth
Original Assignee
Mint Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mint Diagnostics Ltd filed Critical Mint Diagnostics Ltd
Publication of WO2023187384A1 publication Critical patent/WO2023187384A1/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502707—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by the manufacture of the container or its components
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502715—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
    • A61B10/0045—Devices for taking samples of body liquids
    • A61B10/0051—Devices for taking samples of body liquids for taking saliva or sputum samples
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
    • G01N33/5438—Electrodes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
    • A61B2010/0003—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements including means for analysis by an unskilled person
    • A61B2010/0006—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements including means for analysis by an unskilled person involving a colour change
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/06—Fluid handling related problems
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/06—Fluid handling related problems
    • B01L2200/0684—Venting, avoiding backpressure, avoid gas bubbles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/10—Integrating sample preparation and analysis in single entity, e.g. lab-on-a-chip concept
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/02—Identification, exchange or storage of information
    • B01L2300/025—Displaying results or values with integrated means
    • B01L2300/027—Digital display, e.g. LCD, LED
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0627—Sensor or part of a sensor is integrated
    • B01L2300/0636—Integrated biosensor, microarrays
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0627—Sensor or part of a sensor is integrated
    • B01L2300/0645—Electrodes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0809—Geometry, shape and general structure rectangular shaped
    • B01L2300/0816—Cards, e.g. flat sample carriers usually with flow in two horizontal directions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0809—Geometry, shape and general structure rectangular shaped
    • B01L2300/0819—Microarrays; Biochips
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0809—Geometry, shape and general structure rectangular shaped
    • B01L2300/0825—Test strips
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0887—Laminated structure
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/16—Surface properties and coatings
    • B01L2300/161—Control and use of surface tension forces, e.g. hydrophobic, hydrophilic
    • B01L2300/163—Biocompatibility
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/16—Surface properties and coatings
    • B01L2300/161—Control and use of surface tension forces, e.g. hydrophobic, hydrophilic
    • B01L2300/165—Specific details about hydrophobic, oleophobic surfaces
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
    • B01L2400/0406—Moving fluids with specific forces or mechanical means specific forces capillary forces
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/06—Valves, specific forms thereof
    • B01L2400/0688—Valves, specific forms thereof surface tension valves, capillary stop, capillary break
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/08—Regulating or influencing the flow resistance
    • B01L2400/082—Active control of flow resistance, e.g. flow controllers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/50273—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by the means or forces applied to move the fluids

Definitions

  • the present invention generally relates to an integrated fluid sample test strip, a fluid sample test system, and use of the test strip or test system to perform an ELISA or ELONA test.
  • the fluid sample comprises saliva.
  • preferred embodiments measure analyte levels in saliva, for example for hormone testing or monitoring.
  • cortisol is a stress hormone that is generally released in the human body as a result of physical or psychological stressors. Where the stress response is dysregulated, this can lead to broad health problems and/or performance deterioration, with regard to a person’s mental or physical state.
  • Using for example saliva to test for hormones may be desirable.
  • analyte concentrations in saliva can be extremely low.
  • the hormone oestradiol may be present at below picogram/mL levels. Detecting such low concentrations of analytes often requires an assay approach involving amplification.
  • Enzyme-linked immunosorbent assays employ enzymatic amplification to oxidise a substrate species. In the most common form of ELISA the oxidized substrate species are coloured and the intensity of the colour is indicative of the analyte concentration. This approach is known as a colorimetric assay. It is also possible to measure the oxidized substrate species electrochemically to allow greater quantification and sensitivity.
  • a sample is generally prepared and controlled prior to analysis. For example, to carry out an ELISA test for detecting cortisol concentration of saliva, the sample is centrifuged and the pH checked before analysis. Similarly, for a salivary lateral flow test, the saliva is diluted in buffer solutions before analysis.
  • biosensor devices should be suitable for use by an untrained consumer in their own home. Any requirement for multiple reagents and/or sample pre-treatment generally add complexity to the testing protocol and may introduce significant sources of error, and thus are example barriers to home diagnostic tests becoming more prevalent.
  • a further barrier is that, to obtain reliable quantitative results from analysis of saliva using existing methods, relatively large volumes of saliva need to be collected. Saliva collection methods such as passive drooling are required with long collection times, e.g., 15 minutes.
  • GB2593199 (A) generally provides an integrated test strip device for monitoring biomarker levels.
  • the architecture of the test strip device of GB2593199 (A) may introduce a level of uncertainty to the measurement results due to, for example, systematic variability resulting from the wash buffer potentially diluting the substrate to be measured between the incubation and test chamber.
  • the field of fluid sample testing therefore needs an improved method or device to monitor the levels of chosen biomarker(s), e.g., the field of saliva testing needs an improved method or device to monitor such levels in an individual’s saliva.
  • Such an improved method may allow, e.g., a compact and/or portable test apparatus, quantitative measurement, greater convenience for the user, speed, accuracy, sensitivity and/or reliability, and preferably without any requirement of a lab environment, trained professionals and/or sample pre-treatment. It is desirable that the testing needs minimum user intervention or input at any stage after the sample collection and during analysis.
  • an integrated fluid sample test strip comprising: a first layer; an inlet for receiving a series of solutions, said solutions comprising at least a fluid sample and a substrate solution; a test chamber for incubating and performing biosensing tests on one or more solutions received from the inlet, the test chamber formed in the first layer and configured to receive the solutions from the inlet, the test chamber functionalized with one or more bioreceptors for binding to a target analyte, the test chamber comprising a plurality of test electrodes to perform at least part of a biosensing test of the substrate solution; and a second layer comprising a cavity that is adjacent to the test chamber, wherein the cavity is recessed along and under at least part of a sidewall of the test chamber, the second layer comprising a hydrophilic surface adjacent to the first layer.
  • Preferred embodiments may provide advantages such as accuracy, sensitivity and/or reliability of detection or measurement of a target analyte, e.g., biomarker, that may be in received saliva. This is desirable in various fields of activity, such as health or wellness programs for elite sports training and/or precision medicine to allow drugs administration tailored according to a patient, e.g., to their individual hormone levels.
  • a target analyte e.g., biomarker
  • the integrated nature of the strip allows all of the features to be provided to the user within a one-piece device that is preferably portable, compact and/or disposable. While the present disclosure generally refers throughout to assays for testing saliva, e.g., salivary hormone tests, embodiments may additionally or alternatively be suitable for use with one or more other matrices.
  • Such other matrices which may comprise bodily fluids such as blood and/or urine.
  • Further example matrices comprise non-bodily fluids, e.g., water, for example for use in environmental monitoring. Therefore, references to saliva within the present disclosure are generally interchangeable with references to any one or more of such other fluids.
  • the test strip may enable incubation of a sample and a competing conjugate with bioreceptor molecules (such as an antibody or aptamer) followed by a subsequent electrochemical measurement in a single combined incubation and test chamber.
  • bioreceptor molecules such as an antibody or aptamer
  • the incubation of the sample and competing conjugate may be simultaneous or sequential.
  • the architecture may enable precise control of liquid within the microfluidic network, allowing the measurement of analyte levels in an, e.g., saliva, sample in a relatively small amount of time (for example, in less than 1 hour).
  • Embodiments may not require a laboratory setting for operation of the strip and/or for preparation of the saliva sample, and therefore may advantageously allow analysis in a field or point-of-care environment.
  • the inlet may allow solutions and other fluids to be introduced to the test strip (noting that the term ‘fluid’ is used herein to refer to ‘liquid’, e.g. a solution).
  • the inlet is configured to have an external aperture cross-section that is sufficiently wide to ease the introduction, yet is of small enough width (e.g., diameter) to allow dispensed fluids to wet preferably an entire bottom surface of the inlet.
  • a large inlet width/diameter may minimise capillary effects near the external aperture of the inlet, while allowing preferably the entire bottom of the inlet to be wetted by introduced fluids.
  • the width (e.g., diameter) and/or volume of the inlet may therefore vary between different embodiments, depending on the volume of fluids required for a particular assay.
  • the inlet volume may be determined such that an expected combined volume of introduced fluids is greater than the combined internal volume for holding fluid in the test strip downstream of the retention valve. This may allow one or more later introduced fluids to be retained in the inlet.
  • retention of fluid in the inlet may provide additional hydrostatic pressure.
  • the inlet may optionally comprise a retention valve which may reduce (e.g., prevent) air flow into downstream components of the strip, e.g., into the reaction and/or test chamber. This may improve the accuracy, sensitivity and/or reliability of testing.
  • the retention valve may be active or passive, wherein a passive retention valve may have the greatest capillary pressure in substantially (preferably entirely) the whole capillary system of the test strip, e.g., not just higher relative to (immediately) adjacent microfluidic features.
  • the retention valve generally pins the dewetting meniscus.
  • An example passive valve generally comprises a fluid flow path having a constriction, and/or a narrow path relative to at least directly adjacent features from which the fluid flows in and out of the valve, and/or preferably has a smaller cross sectional area for fluid through-flow than any other microfluidic features of the test strip.
  • the valve may be configured to regulate flow of liquid through the valve by means of capillary force.
  • the retention valve may ensure fluidic flow with reduced (preferably complete absence of) air bubbles downstream in the test strip (e.g., in any fluid in flow paths between the retention valve and the capillary pump or the combined incubation and test chamber), and/or may reduce or prevent ‘dead’ volumes where non-specific reactions or binding events (which may be other than those between the analyte of interest and the bioreceptor molecules (antibody and/or aptamer)) may otherwise take place in the test strip.
  • Non-specific reactions or binding events are generally undesirable and may be due to species sticking to the channel surfaces or solution getting trapped in a non-preferred location. Such dead volumes may increase the noise in measurement values, decreasing the accuracy and/or reliability of the test results.
  • the inlet retention valve is configured to have the greatest capillary pressure in the test strip. This may be enabled, for example, by the retention valve having a smaller cross-sectional area than any of the other components of the test strip. This may result in the valve rarely (preferably never) becoming empty of fluid during use of the test strip. (Noting that the term ‘cross-section’ is used herein to refer to an area through which can flow).
  • At least one biosensing test may comprise at least two stages: biorecognition; and an electrochemical transduction.
  • the biorecognition and electrochemical transduction may both occur in the combined incubation and test chamber (alternatively referred to herein as a test chamber, incubation chamber, reaction chamber, measurement chamber and/or sensing chamber).
  • the combined incubation and test chamber may be pre-functionalised with bioreceptor molecules during manufacture of the test strip.
  • bioreceptor molecules may bind with a target analyte in fluids such as solutions introduced into the test strip. This binding may occur due to the biorecognition between the bioreceptor molecule and the target analyte. This may allow test strips to be designed to detect levels of specific target analytes, reduce the number of steps required by the user, and/or improve the reliability of the results in point of care use.
  • the combined incubation and test chamber may be configured to expose solutions to one or more test electrodes.
  • test electrode(s) may be controllable to perform the electrochemical transduction and detect a level of the target analyte in a sample input into the test strip.
  • the test strip may be used for sequential and/or simultaneous competition immunoassays.
  • the electrochemical transductions may be performed on one or more later input fluids (e.g., solutions), rather than directly on a test (e.g., saliva) sample.
  • the test strip may be used for other assay formats.
  • a competitive assay may be preferred, for example because each hormone molecule generally only has one epitope.
  • the architecture of the present invention enables the combination of the test and incubation chambers without resulting in a significant increase in the non-specific signal. It has further been found that the sensors were not significantly passivated by substances present in the sample(s) or the reagents, for example because they may be reduced or removed from the sensors by a wash buffer before the measurement occurs.
  • test electrodes may enable an electrochemical test of a substrate solution. This may facilitate extremely sensitive quantification of, e.g., salivary, hormone concentrations.
  • the integrated test strip may optionally comprise a capillary pump which may allow waste solution(s) to flow through the test strip and away from the microfluidic elements involved in performing the biosensing test, e.g., the reaction and test chamber.
  • the capillary pump may comprise one or more vent holes to allow air in the test strip to evacuate the capillary pump as input fluids flow through the strip.
  • vent hole(s) may reduce, e.g., prevent, any increase in air pressure in the test strip.
  • An increase in air pressure due to, for example, trapped air may reduce the flow rate of the input fluids and/or prevent the fluids from flowing through the test strip.
  • the test strip comprises of at least a first (e.g. polymer) layer and a second (e.g. adhesive) layer with at least one hydrophilic surface; the second layer thus may be referred to as a ‘hydrophilic layer’.
  • the combined incubation and test chamber may be formed in at least the polymer layer, preferably also in an adjacent cavity of the second layer, further preferably such that the entire surface of the second layer that is a surface of the chamber is hydrophilic. (In embodiments, a hydrophilic surface may extend across part(s) or substantially an entirety of the first layer’s interface with the second layer).
  • a recess or undercut may be provided in the second layer around at least part of the combined incubation and test chamber.
  • the provision of the recess may decrease the flow rate of the fluid though the combined incubation and test chamber, and thereby increase the interaction time between the solution and the bioreceptor molecules disposed in the combined incubation and test chamber.
  • a cut edge of the hydrophilic layer around the combined incubation and test chamber may interact with the fluid in the combined incubation and test chamber.
  • some or all of the fluid may flow along the edge of the combined incubation and test chamber.
  • the captured antibodies are generally at the centre of the chamber, but without the recess the fluid may bypass the center of the chamber. In this case, the actual flow rate may decrease, however this may be mostly because the actual cross-section used by the fluid is significantly reduced. Thus, in implementations without the recess, the interaction between the solution and the bioreceptor molecules may be drastically reduced, thereby resulting in a significant reduction in the accuracy of measurement results.
  • fluid flowing along the edge of the combined incubation and test chamber typically flows through a reduced cross-section of the combined test and incubation chamber. Therefore, implementations without this a recess may have a reduced the flow rate of fluid through the combined incubation and test chamber. This in turn may result in a greater level of uncertainty regarding the time required for each step of the assay process, and/or a further potential reduction in the accuracy of measurement results.
  • the hydrophilic layer may be recessed by at least 50pm, for example by 65pm or 100pm along at least part of a sidewall of the combined incubation and test chamber.
  • the hydrophilic layer may be recessed by a distance that is less than a thickness of the hydrophilic layer, in order to assist in reducing the risk of fluids bypassing the test chamber via the recess and/or becoming trapped in the recess.
  • the recessed may be less than 200pm along the whole or part of the sidewall of the combined incubation and test chamber.
  • the combined incubation and test chamber may comprise a tapered or narrowed end for receiving solutions from the inlet.
  • the recess size around the tapered end may be less than the recess size around the rest of the combined incubation and test chamber.
  • the presence of a smaller recess may enable or increase the interaction between the fluids in the combined incubation and test chamber and the edge of the hydrophilic layer, and thereby assist the flow of the fluids into the combined incubation and test chamber.
  • the recess may be less than 50pm along sidewall of the tapered end, and/or the hydrophilic layer may not be recessed at all along the sidewall of the tapered end.
  • a channel for guiding solution from the inlet to the combined incubation and test chamber may be formed in at least the hydrophilic surface of the second layer.
  • the channel may be formed in the first and layer and second layers, e.g. such that the channel comprises a formation in first (polymer) layer and a corresponding cavity, cutting or formation in the second (adhesive) layer.
  • a potential barrier between the channel and the combined incubation and test chamber may result in a variable delay in the time taken for the fluid to enter the combined incubation and test chamber from the inlet.
  • the potential barrier may be reduced (as e.g.
  • the fluid in the channel is no longer in contact with the hydrophilic surface).
  • this may significantly reduce the variability in the time taken for the fluid to enter the combined incubation and test chamber.
  • the variable delay may be reduced to negligible levels, such as under 1 second.
  • an integrated fluid sample test strip comprising: a first layer; a second layer comprising a hydrophilic surface adjacent to the first layer; an inlet for receiving a series of solutions, said solutions comprising at least a fluid sample and a substrate solution; a test chamber for incubating and performing biosensing tests on one or more solutions received from the inlet, the test chamber, the test chamber configured to receive the solutions from the inlet, the test chamber functionalized with one or more bioreceptors for binding to a target analyte, the test chamber comprising a plurality of test electrodes to perform at least part of a biosensing test of the substrate solution; and a channel for guiding a solution from the inlet to the test chamber, wherein the channel is formed in the hydrophilic surface of the second layer.
  • the entire surface of the second layer that is a surface of the chamber is hydrophilic.
  • the hydrophilic surface may extend across part(s) of or substantially an entirety of the first layer’s interface with the second layer.
  • the combined incubation and test chamber may comprise a plurality of test regions, with each test region comprising one or more of the plurality of test electrodes.
  • the plurality of test regions may be separated by a distance greater than the diffusion distance of the solution over the incubation period, to reduce mixing of reagents in the test regions resulting from diffusion.
  • the separation distance may be at least twice the diffusion distance to reduce mixing of the reagents between the test regions.
  • the incubation period may be 15 minutes, however it will be understood that this period is provided as an example, and other incubation periods may be used. Suitable separation distances may include, for example, at least about 0.9mm, or by at least about 1 ,8mm.
  • the combined incubation and test chamber may comprise reduced width sections between some or all of the test regions.
  • the reduced width sections may increase the time required for samples in the fluid to diffuse between different test regions. This in turn may allow the test regions to be more closely spaced, resulting in e.g. a smaller test strip.
  • the provision of multiple separated test regions may allow much easier multiplexing of the measurement results. This is because the fluid may flow in the test strip at a relatively laminar regime (e.g. with a low Reynolds number) given the flow rates involved (e.g. typically 10 - 100 pL/min). This may therefore assist in avoiding turbulent areas with high mixing rates.
  • an integrated fluid sample test strip comprising: i. an inlet for receiving a series of solutions, said solutions comprising at least a fluid sample and a substrate solution, wherein the inlet comprises a retention valve for temporarily retaining each said solution to thereby reduce air flow through the retention valve; ii. a reaction chamber to receive the solutions from the inlet via the retention valve, the reaction chamber functionalized with one or more bioreceptors for binding to a target analyte; iii.
  • a capillary pump to receive from the reaction chamber at least one of the solutions including at least the fluid sample, the capillary pump comprising at least one vent hole to allow any air to escape from the capillary pump and thereby reduce pressure in the capillary pump; iv. a plurality of test chambers to receive the substrate solution from the reaction chamber, the plurality of test chambers each comprising test electrodes to perform at least part of a biosensing test of the substrate solution; v. hydrophobic vent holes coupled to each of the test chambers to allow a flow of solution from the reaction chamber into the test chamber when the vent hole is unsealed and to allow a flow of solution from the reaction chamber to the capillary pump and/or other test chambers when the vent hole is sealed.
  • the capillary pump comprises at least one capillary channel defined by an array of micropillars.
  • a channel may provide capillary pressure, which may enhance or enable flow of solutions into and/or through the capillary pump.
  • At least one said micropillar may comprise a substantially diamond-shaped cross section.
  • Such a shape may be exactly diamond shaped, or may for example have curved corners.
  • a diamond shape may be substantially (e.g., exactly) rhombic.
  • a test strip wherein the capillary pump comprises an internal bypass channel along at least part of a perimeter of the capillary pump, wherein a smallest cross-sectional width of the bypass channel is greater than a smallest separation between adjacent said micropillars.
  • Bypassing flows may be reduced in such an embodiment.
  • Such a bypass channel in the form of a peripheral clearance between a boundary of the capillary pump and the array of micropillars may reduce or prevent bypassing flows along the frame of the micropillar array.
  • test strip wherein a smallest separation between adjacent said micropillars is less than a smallest width of a solution flow path from the reaction chamber to the capillary pump.
  • this may provide a greater capillary pressure in the capillary pump compared to the flow path between the reaction chamber and capillary pump.
  • this may provide a more robust flow of fluids into the capillary pump.
  • the capillary pump has an inlet comprising a constriction.
  • the introduction of a bypass channel may result in a gap between the micropillar array and the pump inlet, and this gap may reduce or prevent flow into the pump.
  • the constriction may reduce the gap between the capillary pump inlet and the micropillar array, and may thereby maintain a capillary pressure at the inlet of the capillary pump and thus aids flow into the pump.
  • test strip wherein: a channel for guiding solution from the test chamber to the capillary pump is formed in at least the first layer; the inlet is formed at in least the first layer; the capillary pump is formed in at least the first layer; the first layer comprises a polymer layer; and/or the second layer comprises an adhesive layer.
  • test strip may in some embodiments be formed within the above-mentioned hydrophilic and/or polymer layers.
  • the test strip may be configured to measure levels of the analyte, wherein the analyte is a hormone. More generally, the analyte may comprise, e.g., be, a hormone and/or biomarker.
  • the test strip may be configured to perform the measurement by performing an ELISA or ELONA (Enzyme-Linked Oligonucleotide Assay) test, and/or other tests.
  • a fluid sample test system comprising the fluid sample test strip and at least one of: a fluid sample collector device for collecting the fluid sample and inputting the fluid sample into the inlet; and a reader device for controlling at least one of the test electrodes to perform the at least part of the biosensing test, and to output a result of the biosensing test.
  • Such a reader device may be used to determine and/or output analyte levels from raw test result data.
  • the reader device may be configured to multiplex measurement results received from one or more test regions; Additionally or alternatively, a fluid sample collector device may be configured to aid in the collection of, and/or input into the inlet of, the fluid sample by the user.
  • Fig. 1 shows an example schematic of a prior art saliva test strip
  • Figs. 2A-E show an example schematic of a saliva test strip and various example layers according to an embodiment of the invention
  • Fig. 3 shows a comparison between example electrode structures of the test strips of Figs. 1 and 2.
  • Fig. 4 shows a comparison between the test chamber of the test strip of Fig. 1 and the Combined Incubation and Test chamber of Fig. 2.
  • Fig. 5 shows a diagram of an example second layer of the test strip according to an embodiment of the invention.
  • Fig. 6 shows illustrative diagrams example Combined Incubation and Test chambers of a test strip according to an embodiment of the invention.
  • Fig. 7 shows an example cross section of a test strip according to an embodiment of the invention.
  • Fig. 8 shows schematically an example electrode configuration of a test strip according to an embodiment of the invention.
  • Fig. 9 shows a flow chart of an example method of measuring analyte concentrations in a saliva sample according to an embodiment of the invention.
  • Fig. 10 illustrates an example competitive assay comprising steps a-d.
  • Fig. 11 shows a block diagram of an example reader device
  • Fig. 12 shows a block diagram of an example collector device
  • Fig. 13 shows a block diagram of an example test system.
  • Fig. 14 shows schematically further example electrode configuration of test strips according to an additional aspects of the invention.
  • Fig. 15a-f illustrate an example flow of fluid through an embodiment of the invention during the method of Fig. 9.
  • Embodiments generally provide a microfluidic apparatus for performing an assay, such as an enzyme- linked immunosorbent Assay.
  • the assay is preferably performed at a point of care, which is generally a location that is convenient to the user and thus preferably not in a dedicated a laboratory.
  • a competitive immunoassay is one where the analytes (e.g. hormone molecules) in a sample (e.g. saliva, blood, urine) and a fixed amount of a labelled analyte analogue (e.g. the “conjugate”; analyte conjugated with a radioisotope, fluorescent or enzyme label) compete for the binding sites on a film with a known amount of immobilised antibody.
  • a labelled analyte analogue e.g. the “conjugate”; analyte conjugated with a radioisotope, fluorescent or enzyme label
  • the amount of analyte is determined by measuring the amount of conjugate that has bound to the antibody (or alternatively, that remains free in solution).
  • a conjugate comprising the hormone of interest and an enzyme such as horseradish peroxidase (HRP) is used.
  • HRP horseradish peroxidase
  • a substrate solution such as hydrogen peroxide with tetramethylbenzidiene (TMB)
  • TMB hydrogen peroxide with tetramethylbenzidiene
  • HRP may oxidise the TMB.
  • the antibodies bind to a higher proportion of conjugates.
  • Oxidised TMB is typically measured colorimetrically (for example, TMB may turn blue or yellow depending on the degree of oxidisation).
  • embodiments of the present invention may measure the TMB electrochemically in order to increase the sensitivity of test, (see ref. Analyst, June 1998, Vol. 123 (1303-1307) by G. Volpe et a/.).
  • a blue product of a HRP/H2O2 + TMB reaction is generally a one-electron oxidation product of TMB.
  • a two-electron oxidation product is generally coloured yellow.
  • the reaction may be stopped by using a strong acid, which may further oxidise the one-electron oxidation products and/or stabilise the system preferably to allow more accurate measurement in a spectrophotometer or plate reader.
  • use of a stop solution in embodiments of the present invention may displace reacted TMB from the reaction chamber.
  • embodiments do not use a stop solution and/or measure the one-electron oxidation product).
  • Fig. 10 shows an example of a sequential addition competitive immunoassay in an embodiment.
  • a sample for example, saliva
  • a target analyte for example, a hormone
  • bioreceptor molecules for example, an antibody
  • an enzyme conjugate for example, HRP
  • a buffer solution is used to remove the remaining unbound enzyme conjugate from the vicinity of the bioreceptor molecules.
  • a substrate solution hydrogen peroxide with tetramethylbenzidiene (TMB)
  • TMB hydrohalogen peroxide with tetramethylbenzidiene
  • the amount of reacted or oxidised substrate solution may be related to the amount of bound enzyme conjugate.
  • the greater the measured oxidation of the TM B the lower the hormone analyte concentration in the saliva sample.
  • Fig. 9 shows an example process 900 for performing a sequential addition competitive immunoassay, such as an ELISA test, using a test strip according to an embodiment.
  • the test strip is inserted into an electronic reader device (however this step could alternatively occur as a final or intermediary step in the process).
  • the reader device may be used to, for example, control the test electrodes and/or provide the test results to the user.
  • a sample containing a target analyte is inserted into the test strip via the inlet.
  • This sample may be, for example, a 10 L saliva sample from the user.
  • the volume of the sample may vary depending on the particulars of e.g. the immunoassay and target analyte.
  • a conjugate solution is inserted into the test strip via the inlet.
  • the conjugate may be mixed with the sample and inserted into the test strip in step 904.
  • the conjugate solution may be, for example, a 10pL solution containing target analyte conjugated with an enzyme.
  • the volume may vary depending on the particulars of the test.
  • a wash buffer solution may be inserted into the test strip via the inlet.
  • the wash buffer helps to prevent contamination of the later substrate solution by the conjugate solution and/or by unbound enzyme-conjugates in the reaction chamber. By reducing the probability of contamination the wash buffer solution may improve the reliability of the results.
  • the wash buffer solution may have a volume of about 25 L.
  • additional wash buffer solutions may be used to further reduce the risk of contamination of the substrate solution.
  • the additional wash buffer solutions may have a volume the same as or different from that of the initial wash buffer solution.
  • a substrate solution may be inserted into the test strip via the inlet.
  • the substrate solution and/or volume used may depend on the target analyte and/or enzyme conjugate.
  • the substrate solution may have a volume of about 10pL.
  • step 914 the user controls the test electrodes in the test chamber to measure the substrate solution. This measurement may be accomplished by using electrochemical transduction to measure the amount of oxidised substrate solution. As discussed above, the test electrodes may be controlled via a reader device, which may then present the results to the user.
  • the user may allow a certain amount of time for the fluids to propagate through the test strip.
  • Possible wait times between each step are shown in Fig. 9.
  • the wait time between each of steps 904, 906 and 908 may be about 10 minutes
  • the wait time between each of steps 908, 910 and 912 may be about 2 minutes
  • the wait time between steps 912 and 914 may be about 10 minutes or 15 minutes.
  • the user may be prompted to proceed to the next step by the reader device, and/or be provided with instructions (separately or by the saliva test system) detailing any such wait time(s).
  • the volumes and/or incubation times discussed with regard to example process 900 can vary.
  • the short (e.g., 2 minute) wait times may allow each added reagent solution to flow into the test strip channels and/or ensure that the next reagent is added to an empty inlet, thereby reducing or avoiding uncontrolled dilution in the inlet.
  • the longer (e.g., 10 minutes or 15 minutes) incubation times may be set according to the specific antigen-antibody reaction times. Such times may be between about 5 minutes and about 30 minutes.
  • reactions in the microfluidic channels may reach equilibrium conditions in a shorter period of time than reactions in e.g. in standard plate wells, due to reduced channel dimensions and subsequently shorter diffusion lengths.
  • Fig. 11 shows a block diagram of an example reader device 1100.
  • the reader device may be any device capable of controlling the test electrodes to perform an electrochemical measurement of the substrate solution, processing of raw test data into analyte concentration and the communication of the analyte concentration to the user, for example via a host computer or mobile phone, and/or by a display on the reader device.
  • the reader device may control the test chamber vent to open, for example by actuation. This actuation may be automatic, or it may be controlled by the user through a user control interface 1110, for example a button or a touch screen display.
  • the reader device is a preferably USB-connected multi-channel potentiostat device that may be controlled by software located on a computing device.
  • the reader device may have a component 1104 configured to communicate with external computing devices, such as a USB port.
  • the reader device may only have one test strip port 1102, however in some embodiments the device may have multiple ports 1102 to enable multiple test strips to be operated simultaneously. For example, a device with 5 ports would enable simultaneous testing with 5 test strips.
  • the reader may be provided with a processor 1106 running software 1112 to guide the user through the multi-step protocol, and/or this functionality may be provided by software on the computing device.
  • the reader device may further be provided with a display screen 1108 for providing information to the user, and/or this functionality may be provided by an external computing device.
  • the reader device may be configured to further process the test data.
  • the reader device may multiplex measurements by adding signals and/or results obtained from measurement electrodes (e.g., working electrodes) from different test regions of the chamber, and thereby obtain multiple measurements and/or integrate positive and/or negative controls by adequately tailoring the biochemical modification of the surface in the incubation chamber.
  • the processing test data (such as multiplexing) may be performed by the reader device itself, or by one or more external computing device(s), such as a mobile phone or a host computer, which may receive test data from the reader device.
  • Such a process may be implemented using test strip embodiments as described in the following. Such embodiments may allow multiple reagent solutions to be added to a test strip in a simple way and/or without the need for any active pumping mechanism.
  • one way to achieve passive pumping of fluids is to utilize capillary pressure.
  • Zimmerman et al (LabChip, 2007, 7, 119-125, Capillary pumps for autonomous capillary systems) defines the capillary pressure Pc of a liquid-air meniscus in a microchannel as: where y is the surface tension of the liquid, a b ,t,i, r are the contact angles of the liquid on the bottom, top, left, and right wall, respectively, and a and b are the depth and width of the microchannel, respectively.
  • Microfluidic components typically have sub-millimeter dimensions and thus may allow for precise control and manipulation of fluids via capillary action.
  • References to microfluidic channels and/or chambers throughout the description generally refer to channels and/or chambers of dimensions at which the mass transport of fluids is primarily governed by capillary pressure.
  • References to capillary pressure herein generally relate to capillary pressure of a saliva-air interface, and may be approximated based on the above equation for capillary pressure Pc based on an assumption that the relevant structure, e.g., channel or chamber, can be approximated as having a substantially rectangular cross-section.
  • liquid-air capillary pressure Pc may generally be applied to references to capillary pressure throughout the present disclosure, for example in relation to the inlet retention valve having a greatest capillary pressure in the test strip, which may in turn specifically relate to capillary pressure of a saliva-air interface.
  • liquid in the channel may be pulled from each end by the capillary pressure (or combined surface tension) at the liquid-air interface. Liquid may flow into the capillary pump when there is liquid in the inlet since the pull from the inlet may be less than the pull from the capillary pump. (In addition to this capillary pressure difference, liquid in the inlet with height greater than the depth of the channels may generally exert a hydrostatic pressure).
  • Inlet and test chamber retention valves jointly may have the greatest capillary pressure in a test strip embodiment.
  • Fig. 1 shows a known saliva test strip 100, such as the test strip device of GB2593199 A1.
  • Test strip 100 has an inlet 102, a microfluidic reaction chamber 106, a capillary pump 110 and a test chamber 116.
  • the reaction chamber 106 is used for incubation or reaction of solution(s) received from the inlet 102, such as saliva, with bioreceptor molecules.
  • Test chamber 116 is provided in a side microfluidic circuit that branches off from the main fluidic channel between reaction chamber 106 and capillary pump 110. The inclusion of an additional side branch in the test strip 100 results in additional dilution and losses of the sample by possible nonspecific adsorption on the device walls, and as therefore reduces the accuracy of the results obtained from any tests.
  • the test chamber 116 includes a vent channel 120 that connects the test chamber 116 to a vent hole 118.
  • the vent hole 118 is initially sealed to reduce flow into the test chamber 116.
  • the user of test strip 100 is therefore required to open the vent hole 118 after a specified amount of time to initiate flow into the test chamber 116 from the reaction chamber 106 after the substrate has incubated with the bioreceptors in the reaction chamber 106.
  • the vent hole 118 is opened by, for example, piercing or removing a cover or film.
  • vent hole 118 The requirement for the user to open the vent hole 118 increases the complexity of the process to the user, and provides an additional source for measurement error, as different users (or even the same user over multiple tests) may open the vent hole 118 at different times even when attempting to follow the same set of instructions. Moreover, the presence of an open hole (e.g. the opened vent hole 118) from which test fluids could escape (e.g. leak) from test strip 100 into the environment represents a potential safety hazard.
  • Fig. 2A shows an example saliva test strip 200.
  • the test strip 200 comprises an inlet that includes an inlet port 202 and a microfluidic retention valve 204 immediately adjacent to inlet port 202.
  • the inlet retention valve 204 may at least temporarily maintain a position of fluid within retention valve 204 when inlet 202 is at least substantially (e.g., fully) otherwise empty of input solution(s).
  • the retention valve may pin the fluid in position once the inlet is effectively empty.
  • the retention valve 204 may help to reduce or avoid bubble formation in a microfluidic channel 208 leading toward the combined incubation and test chamber 206, even upon multiple serial additions of solutions.
  • Inlet 202 is connected to the chamber 206 via inlet retention valve 204 and the microfluidic channel 208.
  • Test strip 200 further comprises a capillary pump 210 that is connected to chamber 206 by a further microfluidic channel.
  • Capillary pump 210 may comprise vent hole(s) 212.
  • the capillary pump 210 has a capillary pressure greater than the rest of microfluidic circuit of test strip 200 except for any microfluidic retention valve(s), such as retention valve 204.
  • test strip 200 does not comprise a dedicated test chamber. Instead, chamber 206 may be used for both the incubation or reaction of solution(s) such as saliva with bioreceptor molecules and the testing and/or measurement of the incubated solution. As such, the combined incubation and test (CIT) chamber 206 may be used for determining hormone and/or other analyte levels in a sample by performing a measuring or sensing test on a solution such as a substrate solution. For example, as discussed in more detail with reference to Fig.
  • a measurement of a level of oxidization of a substrate solution may be used to determine a corresponding analyte level in a test sample. (Embodiments may not measure hormones directly).
  • the CIT chamber 206 may further allow electrochemical measurement of such a solution by exposing the solution to test electrode(s) 216 at one or more test regions 214.
  • the CIT chamber 206 may be pre-functionalised by dispensing bioreceptor molecules along one or more of its surfaces to assist with the incubation or reaction of solution(s).
  • the bioreceptor molecules may comprise, for example, antibodies to bind with a target hormone analyte in a saliva sample.
  • Test strip 200 may therefore improve the accuracy of test results by e.g. reducing the measurement error from dilution and losses by possible nonspecific adsorption on the device walls.
  • test strip 200 therefore may reduce the potential for user error and thereby increases the reliability and/or replicability of the test results.
  • the test strip 200 may comprise a stack formed of a plurality of layers, such as the example layers shown in Figs. 2B-E. Examples of such layers are described below as first to fourth layers, however any one or more of those layers may not be present, and/or additional layer(s) may be provided above, below or inbetween those layers.
  • a first layer 224 shown in Fig. 2E may be an electrode film, for example a Au/PET film, for example a preferably sputtered gold film with a thickness of, e.g., about (i.e., exactly or approximately) 20-1000nm on a PET film. In one embodiment a thickness of about 50nm is used, and/or the Au/PET film has a square resistance of 5 £)/ ⁇ .
  • the gold may be patterned for example by laser ablation to form an electrical circuit for use in an electrochemical measurement.
  • the electrodes may be screen printed electrodes or part of a circuit formed by lithographic processes.
  • a second layer 222 shown in Fig. 2D may be a laminate layer such as a 2-ply laminate stack of a doublesided adhesive film (such as PET with inert, acrylic, pressure-sensitive and/or medical-grade adhesive on each side) with a preferably single-side adhesive film (such as PET with preferably hydrophilic and/or pressure-sensitive adhesive).
  • laminate layer may comprise a single preferably double-sided adhesive film, where the adhesive on at least one side may be hydrophilic.
  • the laminate stack may have a thickness of between about 5 pm and about 300 pm. More specifically, an example thickness may be approximately 200 pm, e.g., 183 pm.
  • the second layer may comprise formations, cuttings and/or cavities corresponding to, for example, one or more of the inlet 202, channel 208 and CIT chamber 206.
  • a third layer 220 shown in Fig. 2C may comprise a microfluidic cartridge such as a PMMA layer.
  • the PMMA layer may have a thickness of greater than about 0.5 mm.
  • a preferred embodiment may have a thickness of at least 2mm.
  • the microfluidic channels including for example the inlet and/or CIT chamber, may be formed by laser ablation, injection moulding and/or hot embossing. Additional or alternative polymers may include cyclic olefin polymer (COP), cyclic olefin copolymer (COC), polycarbonate (PC) and/or polystyrene (PS).
  • COP cyclic olefin polymer
  • COC cyclic olefin copolymer
  • PC polycarbonate
  • PS polystyrene
  • the depths of the channels in this layer may be less than or about 300pm.
  • a total thickness of at least 2mm may be preferred to provide a sufficient inlet volume such that dispensed reagent volumes may be confined.
  • a thinner PMMA cartridge may have a wider inlet area to compensate for the lost volume.
  • the depths of the channels along with the channel width and length may define the volume capacity of the test strip, and the reagent volumes may be set accordingly.
  • Thin of the cartridge may be driven by volumes such as capacity of the test strip in total, balance between reaction and test chamber volumes, and/or maximum reagent volume to be added to the test strip.
  • the channels themselves may be less than about 0.3mm deep so that the strip could then be about 0.5mm thick to robustly accommodate these.
  • the inlet capacity is preferably suitable to hold this without overflowing.
  • a thinner PMMA strip of thickness say, about 0.5mm and a separate inlet apparatus may increase the capacity there).
  • a fourth layer may comprise a test strip label and may be a printed and/or die-cut PVC (vinyl) or PET (polyester terephthalate) label.
  • the test strip label may include test strip information and/or branding for the test strip.
  • the label may screen the CIT chamber 206 from exposure to light. This may be advantageous, as light exposure can oxidise a TMB substrate and reduce accuracy of any measurement.
  • Fig. 3 shows a comparison of the electrode structure 302 of a test strip 100 of Fig. 1 and an example electrode structure 304 of test strip 200 of Fig. 2.
  • the measurement electrodes of test strip 100 are configured to allow electrochemical measurements of a solution in a dedicated measurement chamber that forms part of an additional side branch of the fluidic circuit.
  • the measurement electrodes of test strip 200 are configured to allow electrochemical measurements of a solution or solutions in a multi-purpose chamber that may also be utilized for e.g. incubating or enabling reactions of the solutions.
  • Fig. 4 shows a comparison of the measurement chamber 116 of test strip 100 of Fig. 1 and an example CIT chamber 206 of test strip 200 of Fig. 2.
  • the CIT chamber 206 may be formed in a polymer layer of the test strip (e.g. the third (PMMA) layer as described above).
  • the CIT chamber 206 may be formed, for example, by injection molding techniques. Formation by this or similar methods may enable increased control over the volume and shape of the CIT chamber 206.
  • the size of the test chamber 116 is defined by a deformable layer, such as the second (laminate) layer described above. This may result in a greater variability in the volume of the test chamber 116 as compared to CIT chamber 206, and thus a reduced accuracy of the measurement results.
  • Figs. 5 and 6 show diagrams of example adhesive layers 500 and 600.
  • the adhesive layers may correspond to the second (laminate) layers described above. In both cases, one or more surfaces of the adhesive layers 500, 600 may be or comprise a hydrophilic surface. As such, adhesive layers 500, 600 may alternatively be referred to alternatively as hydrophilic and/or laminate layers.
  • the adhesive layer 500 may comprise cuttings, cavities or formations corresponding to an inlet 502, retention valve 504, channel 506 and CIT chamber 508.
  • the potential energy barrier between the channel and the CIT chamber of the test strip 200 may introduce a variable delay into the time for the fluid to flow into the CIT chamber from the inlet. In some example devices, this delay may vary between as much as 30 and 90 seconds. The variability of this delay may reduce the reliability of the measurement results by e.g. altering the wait time between the user steps shown in Fig. 9.
  • the potential barrier may be reduced as the fluid in the channel is no longer in contact with a hydrophobic surface. This can be shown by considering the extended Bernoulli equation along a central fluid line: v2 2 ⁇ V r 2 z P 2 - Pi
  • v is the fluid velocity
  • p is the fluid density
  • P is the pressure
  • gZ is the potential energy of the fluid.
  • Subscripts 1 and 2 correspond to the fluid in the channel and the CIT chamber respectively.
  • the presence of channel 506 cut into the adhesive layer may result in a reduction or, preferably, a removal of the potential energy term g(z2 - zi), and therefore may further result in a corresponding reduction in the kinetic energy required by the fluid to enter the CIT chamber.
  • the variability of the delay, and in some cases the delay itself may be reduced.
  • the variability and/or the delay itself may be reduced to about or under 1 second. Delays of this level may have only minor or negligible effects on the measurement results.
  • the inlet, retention valve, channel and chamber may also comprise corresponding formations in other layers of the test strip, for example in a polymer (e.g. third) layer.
  • the cuttings, cavities and/or formations in the adhesive layer may have different dimensions compared to the corresponding formations in one or more other layers.
  • the CIT chamber cavity 508 in the adhesive layer 500 may be larger than the corresponding CIT chamber formed in e.g. the polymer layer.
  • the adhesive layer when part of a test strip the adhesive layer may therefore comprise a recess 602 about the CIT chamber. This is shown in Fig. 6A-D, which show a test strip comprising an example adhesive layers 600 and an example polymer layer 606.
  • the recess 602 When formed into such a test strip, the recess 602 may be provided along and under at least part of a sidewall of the CIT chamber of the polymer layer 606. It will be understood that the term “under” is used herein in a nonlimiting manner, and in embodiments which provide an adhesive layer “above” the polymer layer 606 recess 602 may be instead provided along and above at least part of a sidewall of the CIT chamber of the polymer layer 606.
  • one or more surfaces of the adhesive layer 600 may be a hydrophilic surface.
  • the presence of the hydrophilic walls of the exposed cut adhesive layer 600 around the CIT chamber may result in fluid flowing along the walls of the CIT chamber due to the interaction of the fluid with a hydrophilic surface of the exposed adhesive layer 600.
  • a large enough proportion of the fluid may flow along the edge of the CIT chamber that the interaction between the fluid solution and some, most or even all of the antibodies disposed in the CIT chamber is reduced. This may result in a reduction in the accuracy of any measurements, particularly in e.g. ELISA arrays.
  • the recess 602 in the adhesive layer 600 may reduce the interaction between the fluid and the hydrophilic surface(s) of the cut adhesive layer 600, thereby reducing the risk of fluid bypassing some, most or all of the bioreceptor molecules in the CIT chamber by flowing along the edge of the CIT chamber. This may in turn increase the interaction between the fluid and the antibodies.
  • the recess 602 may be at least 50pm, for example 65pm.
  • the recess 602 distance may additionally be less than the thickness of the adhesive layer 600, for example the recess distance may be less than 200pm.
  • the test strip may comprise tapered or narrowed end regions 604 at one or both of the inlet end 608 and the outlet end of the CIT chamber.
  • the recess 602 in the adhesive layer 600 about the CIT chamber may be less than 50pm at one or both of the tapered end regions 604 of the CIT chamber.
  • the adhesive layer 600 at the entrance 608 to the CIT chamber i.e. the end of the chamber for receiving fluids from the inlet
  • may have no recess 602 or may have a variable recess 602 that increases to e.g. 50pm or more at the end of the tapered region 604.
  • the reduced recess 602 in the tapered region(s) 604 may assist in increasing the flow rate of the fluid into and/or out of the CIT chamber.
  • the reduced recess size in these regions 604 may therefore further assist in overcoming any remaining potential barrier between the channel and the CIT chamber.
  • the example test strip 700 comprises a polymer layer 702 and a laminate layer 704.
  • the laminate layer may comprise, for example one or more adhesive layers and one or more hydrophilic surfaces.
  • a channel 706 and CIT chamber 710 are formed in the polymer layer 702. Additionally, corresponding cuts and/or formations may be provided in the laminate layer 704, for example channel formation 708 and CIT chamber formation 714.
  • the CIT chamber formation 714 may additionally comprise recesses 712 around at least part of the CIT chamber 710.
  • the recesses 712 may have a size D that is, for example, between 50pm and 200pm, such as 65pm or 100pm.
  • channel formation 708 may assist in reducing a variable delay in the time taken for fluid to flow from the channel 706 to the CIT chamber 710.
  • the recesses 712 may assist in increasing the interaction between the fluid (e.g. solutions and/or a sample) and biorecepters (such as antibodies) disposed on the polymer layer 702, for example in the CIT chamber 710.
  • Fig. 8 shows a further example of an electrode structure suitable for use with a test strip 800 according to the present invention.
  • the electrodes 802a-e correspond to three test regions 804, 806 and 808 in the CIT chamber. It will be understood that fewer or additional test regions may also be provided.
  • the provision of multiple test regions 804, 806, 808 may enable the test strip to be used to obtain multiple measurements and/or to integrate positive and/or negative controls by adequately tailoring the biochemical modification of the surface in the GIT chamber.
  • the multiple measurements may then be multiplexed by e.g. a reader device or an external computing device.
  • test regions 804, 806, 808 may be separated to isolate the sample(s) and/or solution(s) of each test region 804, 806, 808 during the incubation and measurement periods.
  • the distance L between the samples may be selected based on the expected diffusion time during the duration T of the incubation and/or measurement period using the equation:
  • test strip may be configured to perform an assay with an incubation period of 15 minutes using a solution with a diffusion coefficient D of approximately 10' 9 m 2 /s.
  • a test strip would preferably have a separation distance L between the test regions 804, 806, 808 of at least 0.9mm.
  • the separation distance between the test regions 804, 806, 808 may be doubled to reduce the mixing of the solutions from the test regions 804, 806, 808 during the incubation period.
  • a separation distance of 2L, or 1.8mm may be used.
  • the interaction between the test electrodes 802 of each test region 804, 806, 808 and reagents produced in different test regions 804, 806, 808 may be reduced. This is because the incubation period may not provide a sufficient time for diffusion between the test regions 804, 806, 808.
  • the CIT chamber may be modified to comprise narrower and/or shallower sections (e.g. reduced width and/or depth sections) between the test regions 804, 806, 808. The narrower and/or shallower regions may slow the diffusion of molecules in these sections, and therefore may slow the diffusion of molecules between test regions 804, 806, 808.
  • narrower and/or shallower regions may therefore allow the separation distance L between the test regions 804, 806, 808 to be reduced. It will be appreciated that the narrower and/or shallower regions may be provided between only some but not all test regions (e.g. between test regions 804 and 806 only, or between test regions 806 and 808 only), or they may be provided between each of the test regions.
  • Fig. 12 shows a block diagram of an example sample collection device 1200.
  • the sample collection device may comprise an inlet 1202 for receiving a sample, a storage chamber 1206 for storing a received sample and an outlet 1206 for inserting the sample into a test strip.
  • the collector device may additionally or alternatively be used to insert other fluids, such as a substrate solution or wash buffer, into the test strip.
  • the inlet 1202 may also be the outlet 1206.
  • Storage chamber 1206 may be designed to hold a suitable volume of a sample for use in a test strip.
  • Fig. 13 shows a block diagram of an example test system 1300 comprising a test strip 1302, a collection device 1304 and a reader device 1306.
  • the test strip 1302 may be, for example, test strip 200 of Fig. 2.
  • collection device 1304 and reader device 1306 may be e.g. collection device 1200 of Fig. 12 and reader device 1100 of Fig. 11 respectively.
  • Figs. 14 shows a further schematic diagram of suitable electrode structures for use with test strips according to the present invention.
  • the electrode structure of Fig. 14a corresponds to the electrode structure of test strip 800 of Fig. 8.
  • Figs. 14b and c show schematic diagrams of alternative methods of providing multiple test regions.
  • multiple test chambers 1402 are provided, each test chamber 1402 corresponding to a test region 1404.
  • the flow of the fluids into and around the test chambers 1402 may be controlled in a similar manner to the flow of fluids in and around the test chamber of test strip 100 of Fig. 1 (for example, via opening of the corresponding vent holes 1406 of each of the test chambers 1402).
  • Fig. 15 outlines an example operational flow of the above-mentioned process 900 through example test strip 1500.
  • steps a) - f any one or more of which may be optional.
  • a sample such as saliva is added into inlet 1502.
  • the sample flows through the test strip and into capillary pump 1508 via the CIT chamber 1506 and the connecting microfluidic channels, such as inlet channel 1504.
  • vent holes 1510 may allow air in capillary pump to be displaced or escape.
  • target analytes such as hormones
  • inlet 1502 preferably becomes empty, however an inlet retention valve may be provided to preferably retain a portion of the sample.
  • a conjugate solution (shown in green) may be inserted into inlet 1502.
  • the conjugate solution may be, for example, a solution formed of the target analyte conjugated with an enzyme.
  • the solution may flow into the test strip in the same way as the sample, displacing the sample through the test strip and into capillary pump 1508.
  • inlet 1502 preferably becomes empty as the conjugate solution flows into the test strip, however the inlet retention valve may again retain a portion of the conjugate solution.
  • the conjugate may no longer be retained by the inlet retention valve.
  • the conjugate may bind with at least some of the remaining unbound bioreceptor molecules. At this stage many (preferably most or all) of the bioreceptor molecules may be bound to either the target analyte or the conjugate.
  • a wash buffer solution (shown in red) may be placed in inlet 1502.
  • the wash buffer solution may displace the conjugate solution through the test strip and into the capillary pump 1508.
  • the wash buffer solution may reduce the number of unbound conjugate molecules in the CIT chamber 1506. This may prevent the removed conjugates from potentially reacting with later solutions and reducing the reliability of test results.
  • inlet 1502 preferably becomes empty as the wash buffer flows into the test strip, however the inlet retention valve may retain a portion of the wash buffer solution. As the wash buffer has displaced the conjugate solution, the conjugate may then no longer be retained by the inlet retention valve.
  • step d one or more additional wash buffer solutions (also shown in red) are added to inlet 1502. These additional buffers may displace the previous solutions as discussed in the previous steps. Each additional wash buffer inserted into the test strip may further reduce the number of unbound conjugate molecules in the CIT chamber 1506, further improving the accuracy and/or reliability of the test.
  • a substrate solution (shown in dark blue) is introduced into inlet 1502.
  • the substrate solution may flow through the test strip, displacing the previous solutions such as the wash buffer into capillary pump 1508.
  • Substrate solution in the CIT chamber 1506 may incubate by reacting with the bound enzymeconjugate molecules. Such reaction may comprise oxidisation of the substrate solution.
  • the incubating/incubated substrate solution is shown in steps e) and f) in purple.
  • the total volume of the fluids introduced to the test strip by this stage should preferably not exceed the total volume of the microfluidic circuit, in order to reduce leakage from vents 1510.
  • the inlet retention valve may retain a portion of the substrate solution as discussed for other solutions above, to ensure that there is remaining solution in inlet 1502 during the substrate incubation.
  • this may increase the hydrostatic pressure in the test strip 1500.
  • the increased hydrostatic pressure may in turn lead to parasitic movement of the substrate relative to the test electrodes.
  • This movement may lead to a change in the location of the test electrodes relative to the intended test areas in the CIT chamber 1506, thereby reducing the accuracy of the measurement results.
  • the movement may also lead to a change in the portion of the substrate in close contact with the immobilised enzyme conjugate. This may result in a greater volume of the substrate solution (e.g. TMB) reacting with the enzyme less intensely compared to a static volume of the substrate solution.
  • the portion to be measured by the electrodes would therefore be less oxidised and ultimately introduce additional error and reduce accuracy.
  • step f) after a preferably predetermined incubation period (for example 10 or 15 minutes) the user or reader device may initiate testing of the incubated substrate solution (i.e. the purple solution).
  • a stationary or slow flowing solution will generally produce more accurate results than a faster flowing solution.
  • a portion of the substrate solution is preferably retained by inlet retention valve, such that the hydrostatic pressure assists in reducing the flow speed of the solution in the CIT chamber 1506.
  • the test electrodes may be controlled (for example, by means of a reader device or other computing device such as a general purpose computer or mobile computing device) to perform an electrochemical transduction. Generally, for a given incubation period, the greater the proportion of bound enzyme-conjugates the more reacted substrate solution will be produced.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Clinical Laboratory Science (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Medical Informatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Sampling And Sample Adjustment (AREA)

Abstract

Une bandelette de test d'échantillon de fluide intégrée comprend une première couche, une entrée pour recevoir une série de solutions, lesdites solutions comprenant au moins un échantillon de fluide et une solution de substrat et une chambre de test pour incuber et effectuer des tests de biodétection sur une ou plusieurs solutions reçues par l'entrée, la chambre de test étant formée dans la première couche et conçue pour recevoir les solutions à partir de l'entrée. La chambre de test est fonctionnalisée avec un ou plusieurs biorécepteurs pour une liaison à un analyte cible, et comprend une pluralité d'électrodes de test pour effectuer au moins une partie d'un test de biodétection de la solution de substrat. La bandelette de test comprend en outre : une seconde couche présentant une cavité qui est adjacente à la chambre de test, la cavité étant évidée le long et sous au moins une partie d'une paroi latérale de la chambre de test, la seconde couche comprenant une surface hydrophile adjacente à la première couche ; et/ou un canal pour guider une solution de l'entrée à la chambre de test, le canal étant formé dans au moins la surface hydrophile de la seconde couche.
PCT/GB2023/050832 2022-04-01 2023-03-30 Collecte et test microfluidiques WO2023187384A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2204764.1A GB2617194A (en) 2022-04-01 2022-04-01 Microfluidic collection and test
GB2204764.1 2022-04-01

Publications (1)

Publication Number Publication Date
WO2023187384A1 true WO2023187384A1 (fr) 2023-10-05

Family

ID=81581460

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2023/050832 WO2023187384A1 (fr) 2022-04-01 2023-03-30 Collecte et test microfluidiques

Country Status (2)

Country Link
GB (1) GB2617194A (fr)
WO (1) WO2023187384A1 (fr)

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248598B1 (en) 1998-09-17 2001-06-19 Stuart C. Bogema Immunoassay that provides for both collection of saliva and assay of saliva for one or more analytes with visual readout
US20070015286A1 (en) 2005-07-15 2007-01-18 Neel Gary T Diagnostic strip coding system and related methods of use
US20090306543A1 (en) 2008-04-07 2009-12-10 Bamburgh Marrsh Llc Specimen Sample Collection Device and Test System
US20100206748A1 (en) 2007-08-01 2010-08-19 Nipro Corporation Stress Measurement Kit and Stress Measurement Method
WO2011030093A1 (fr) 2009-09-04 2011-03-17 Lifescan Scotland Limited Procédé et système de mesure du glucose
US20110108440A1 (en) 2009-11-10 2011-05-12 Bayer Healthcare Llc Underfill Recognition System for a Biosensor
US20110174616A1 (en) 2005-10-17 2011-07-21 Lifescan, Inc. Methods for measuring physiological fluids
WO2014181753A1 (fr) 2013-05-10 2014-11-13 ニプロ株式会社 Dispositif de mesure
US9207244B2 (en) 2013-03-11 2015-12-08 Cue Inc. Systems and methods for detection and quantification of analytes
US9223855B1 (en) 2013-09-20 2015-12-29 Sparta Performance Science Llc Method and system for training athletes based on athletic signatures and a classification thereof
US20160313313A1 (en) 2014-01-16 2016-10-27 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Lateral flow assay apparatus and method, and sensor therfor
WO2017025921A1 (fr) 2015-08-13 2017-02-16 Victoria Link Limited Biocapteurs à base d'aptamères utiles pour détecter des hormones, des hormonomimétiques et des métabolites de ces derniers
WO2017132565A1 (fr) 2016-01-29 2017-08-03 Arizona Board Of Regents On Behalf Of Arizona State University Dispositifs et procédés de mesure du glucose dans la salive
US20170226557A1 (en) 2014-05-30 2017-08-10 The Regents Of The University Of California Strip-based electrochemical sensors for quantitative analysis of analytes
GB2593199A (en) 2020-03-19 2021-09-22 Mint Diagnostics Ltd Microfluidic point-of-care assay
WO2022036346A1 (fr) * 2020-08-11 2022-02-17 Colorado State University Research Foundation Dispositifs de dosage microfluidique électrochimique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101983593B1 (ko) * 2012-08-29 2019-05-29 주식회사 미코바이오메드 히터 유닛이 반복 배치된 열 블록을 포함하는 전기화학적 신호를 검출하기 위한 ｐｃｒ 칩, 이를 포함하는 ｐｃｒ 장치, 및 이를 이용한 실시간 ｐｃｒ 방법
US11480567B2 (en) * 2017-02-15 2022-10-25 New Jersey Institute Of Technology Enhanced sensitivity and specificity for point-of-care (POC) micro biochip
EP3607324A4 (fr) * 2017-04-07 2021-01-13 Tokitae LLC Dispositif d'analyse d'écoulement comprenant au moins une vanne de commande de débit à actionnement électrique et procédés associés
US11020740B2 (en) * 2017-10-24 2021-06-01 New Jersey Institute Of Technology Microfluidic biochip with enhanced sensitivity

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248598B1 (en) 1998-09-17 2001-06-19 Stuart C. Bogema Immunoassay that provides for both collection of saliva and assay of saliva for one or more analytes with visual readout
US20070015286A1 (en) 2005-07-15 2007-01-18 Neel Gary T Diagnostic strip coding system and related methods of use
US20110174616A1 (en) 2005-10-17 2011-07-21 Lifescan, Inc. Methods for measuring physiological fluids
US20100206748A1 (en) 2007-08-01 2010-08-19 Nipro Corporation Stress Measurement Kit and Stress Measurement Method
US20090306543A1 (en) 2008-04-07 2009-12-10 Bamburgh Marrsh Llc Specimen Sample Collection Device and Test System
WO2011030093A1 (fr) 2009-09-04 2011-03-17 Lifescan Scotland Limited Procédé et système de mesure du glucose
US20110108440A1 (en) 2009-11-10 2011-05-12 Bayer Healthcare Llc Underfill Recognition System for a Biosensor
US9207244B2 (en) 2013-03-11 2015-12-08 Cue Inc. Systems and methods for detection and quantification of analytes
WO2014181753A1 (fr) 2013-05-10 2014-11-13 ニプロ株式会社 Dispositif de mesure
US9223855B1 (en) 2013-09-20 2015-12-29 Sparta Performance Science Llc Method and system for training athletes based on athletic signatures and a classification thereof
US20160313313A1 (en) 2014-01-16 2016-10-27 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Lateral flow assay apparatus and method, and sensor therfor
US20170226557A1 (en) 2014-05-30 2017-08-10 The Regents Of The University Of California Strip-based electrochemical sensors for quantitative analysis of analytes
WO2017025921A1 (fr) 2015-08-13 2017-02-16 Victoria Link Limited Biocapteurs à base d'aptamères utiles pour détecter des hormones, des hormonomimétiques et des métabolites de ces derniers
WO2017132565A1 (fr) 2016-01-29 2017-08-03 Arizona Board Of Regents On Behalf Of Arizona State University Dispositifs et procédés de mesure du glucose dans la salive
GB2593199A (en) 2020-03-19 2021-09-22 Mint Diagnostics Ltd Microfluidic point-of-care assay
WO2022036346A1 (fr) * 2020-08-11 2022-02-17 Colorado State University Research Foundation Dispositifs de dosage microfluidique électrochimique

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DONG ET AL.: "ELISA-type assays of trace biomarkers using microfluidic methods", WIRES NANOMED NANOBIOTECHNO, vol. 9, 2017, pages e1457, XP055683372, DOI: 10.1002/wnan.1457
EVANS ET AL.: "A Novel Microfluidic Point-of-Care Biosensor System on Printed Circuit Board for Cytokine Detection", SENSORS, vol. 18, 2018, pages 4011
G. VOLPE ET AL., ANALYST, vol. 123, June 1998 (1998-06-01), pages 1303 - 1307
MOSCHOU ET AL.: "The lab-on-PCB approach: tackling the µTAS commercial upscaling bottleneck", LAB CHIP, vol. 17, 2017, pages 1388
MOU ET AL.: "Materials for Microfluidic Immunoassays: A Review", ADV. HEALTHCARE MATER., vol. 6, 2017, pages 1601403, XP055765328, DOI: 10.1002/adhm.201601403
SAMPER ISABELLE C. ET AL: "Electrochemical Capillary-Flow Immunoassay for Detecting Anti-SARS-CoV-2 Nucleocapsid Protein Antibodies at the Point of Care", ACS SENSORS, 16 November 2021 (2021-11-16), US, pages A - I, XP055862126, ISSN: 2379-3694, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acssensors.1c01527> DOI: 10.1021/acssensors.1c01527 *
ZIMMERMAN ET AL.: "Capillary pumps for autonomous capillary systems", LABCHIP, vol. 7, 2007, pages 119 - 125
ZIMMERMAN ET AL.: "LabChip", CAPILLARY PUMPS FOR AUTONOMOUS CAPILLARY SYSTEMS, vol. 7, 2007, pages 119 - 125

Also Published As

Publication number Publication date
GB2617194A (en) 2023-10-04
GB202204764D0 (en) 2022-05-18

Similar Documents

Publication Publication Date Title
US11026611B2 (en) Rotatable disk-shaped fluid sample collection device
US11287424B2 (en) Calibrating assays using reaction time
JP5661867B2 (ja) 流体コネクタおよびマイクロ流体システム
EP2529220B1 (fr) Dispositif microfluidique centrifuge et procédé de détection de substances à analyser dans échantillon liquide
EP2777499B1 (fr) Dispositif de collecte d&#39;échantillon de fluide rotatif
EP2618153B1 (fr) Régulation d&#39;écoulement de fluide à travers un dispositif de dosage
KR101930610B1 (ko) 생물학적 샘플을 분석하기 위한 회전가능한 카트리지
US20070099290A1 (en) Customizable chip and method of manufacturing the same
US10514354B2 (en) Biosensor structures for improved point of care testing and methods of manufacture thereof
US20230142816A1 (en) Microfluidic point-of-care assay
CN111774104A (zh) 微流控芯片及体外检测装置
CN114814261B (zh) 一种自动化化学发光免疫分析芯片及其检测方法
EP1711827B1 (fr) Procede et element de detection
US20220260556A1 (en) Saliva testing
CA2802258A1 (fr) Dispositif d&#39;essai a faible volume a sensibilite accrue
JP2018515777A (ja) アッセイデバイス中の液体試料の流動を改善する方法
WO2023187384A1 (fr) Collecte et test microfluidiques
CN212632728U (zh) 微流控芯片及体外检测装置
US12123870B2 (en) Fluidic system for performing assays
US9274107B2 (en) Microchip, measurement system and method using the same, and test reagent to be used for microchip

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23717616

Country of ref document: EP

Kind code of ref document: A1